The Potential of Human Papillomavirus Vaccines

Open Access
Publisher Website
Google Scholar
Abstract
The anticipated licensure within the next three months of a vaccine against human papillomavirus (HPV) would represent a major public health advance against cervical cancer and other, less common cancers, including those of the anus, penis, vagina, and vulva. The Food and Drug Administration (FDA) is conducting a six-month priority review of Merck's investigational HPV vaccine and should announce its licensing decision by June 8. Questions remain, however, about the potential behavioral consequences of routinely vaccinating adolescents against a sexually acquired infection, and the public reaction is uncertain.